Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | 177Lu-J591 + Enzalutamide + Prednisolone |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| 177Lu-J591 | Lu 177 rosopatamab tetraxetan|Lu 177 MOAB J591|177Lu-DOTA-TLX591 | PSMA Antibody 20 | 177Lu-J591 is a radioconjugate comprising the radionuclide lutetium-177 linked to a monoclonal antibody that targets PSMA (J591), which delivers radiation to PSMA-expressing tumor cells, potentially resulting in increased tumor cell death (PMID: 16203821). | |
| Enzalutamide | Xtandi | MDV3100|ASP9785 | Hormone - Anti-androgens 54 | Xtandi (enzalutamide) is a second-generation small molecule inhibitor of androgen receptor, thereby resulting in decreased tumor growth (PMID: 24009414, PMID: 25945058). Xtandi (enzalutamide) is FDA-approved for use in patients with castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, and non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis (FDA.gov). |
| Prednisolone | Omnipred | Deltahydrocortisone |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06520345 | Phase III | Abiraterone + Methylprednisolone Docetaxel + Prednisolone Abiraterone + Dexamethasone Docetaxel + Prednisone Abiraterone + Prednisone 177Lu-J591 + Docetaxel + Prednisone 177Lu-J591 + Enzalutamide + Prednisone 177Lu-J591 + Abiraterone + Methylprednisolone 177Lu-J591 + Abiraterone + Dexamethasone 177Lu-J591 + Docetaxel + Prednisolone Enzalutamide + Prednisolone Enzalutamide + Prednisone 177Lu-J591 + Enzalutamide + Prednisolone Abiraterone + Prednisolone 177Lu-J591 + Abiraterone + Prednisone 177Lu-J591 + Abiraterone + Prednisolone | The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT GLOBAL) | Recruiting | USA | AUS | 0 |
CKB BOOST